Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4D | Q08499 | 3/20 | 0.43 |
| ▸ | PDE4A | P27815 | 2/20 | 0.43 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.43 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.43 |
| ▸ | FPR2 | P25090 | 7/20 | 0.33 |
| ▸ | ERN1 | O75460 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | CASP1 | P29466 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | FFAR2 | O15552 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.31 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.31 |
| ▸ | NAMPT | P43490 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1411013 | 1.00 | PDE4D (0.43) | PDE4DPDE4APDE4BPDE4CFPR2 | |
| SCHEMBL2267064 | 1.00 | PDE4D (0.43) | PDE4DPDE4APDE4BPDE4CFPR2 | |
| SCHEMBL14911084 | 1.00 | PDE4D (0.43) | PDE4DPDE4APDE4BPDE4CFPR2 | |
| Bromide SCHEMBL1411487 | 0.99 | PDE4D (0.42) | PDE4DPDE4APDE4BPDE4CFPR2 | |
| Hydrochloric Acid SCHEMBL4399120 | 0.99 | PDE4D (0.42) | PDE4DPDE4APDE4BPDE4CFPR2 | |
| Hydrochloric Acid SCHEMBL4399123 | 0.99 | PDE4D (0.42) | PDE4DPDE4APDE4BPDE4CFPR2 | |
| Hydrochloric Acid SCHEMBL1411249 | 0.99 | PDE4D (0.42) | PDE4DPDE4APDE4BPDE4CFPR2 | |
| Sulfuric Acid SCHEMBL1411894 | 0.96 | PDE4D (0.43) | PDE4DPDE4APDE4BPDE4CFPR2 | |
| Oxalic Acid SCHEMBL1411740 | 0.96 | PDE4D (0.43) | PDE4DPDE4APDE4BPDE4CFPR2 | |
| SCHEMBL1411308 | 0.95 | PDE4D (0.43) | PDE4DPDE4APDE4BPDE4CFPR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 71 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9962377-B2 | Hydroxy-6-heteroarylphenanthridines and their use as PDE4 inhibitors | TAKEDA GMBH (DE) | 2018-05-08 | — | — | US | claimed |
| US-20160279120-A1 | NOVEL HYDROXY-6-HETEROARYLPHENANTHRIDINES AND THEIR USE AS PDE4 INHIBITORS | TAKEDA GMBH (DE) | 2016-09-29 | — | — | US | claimed |
| US-8883818-B2 | Hydroxy-6-heteroarylphenanthridines and their use as PDE4 inhibitors | TAKEDA GMBH (DE) | 2014-11-11 | — | — | US | claimed |
| US-8829189-B2 | Salts of 6-heterocycle substituted hexahydrophenanthridine derivatives | TAKEDA GMBH (DE) | 2014-09-09 | — | — | US | claimed |
| US-20140073636-A1 | NOVEL HYDROXY-6-HETEROARYLPHENANTHRIDINES AND THEIR USE AS PDE4 INHIBITORS | TAKEDA GMBH (DE) | 2014-03-13 | — | — | US | claimed |
| US-20140039001-A1 | NOVEL SALTS OF 6-HETEROCYCLE SUBSTITUTED HEXAHYDROPHENANTHRIDINE DERIVATIVES | TAKEDA GMBH (DE) | 2014-02-06 | — | — | US | claimed |
| EP-2189454-B1 | Novel salts of 6-heterocyclyl substituted hexahydrophenanthridine derivatives | TAKEDA GMBH (DE) | 2013-09-25 | — | — | EP | claimed |
| EP-1723135-B1 | NOVEL HYDROXY-6-HEROARYLPHENANTHRIDINES AND THEIR USE AS PDE4 INHIBITORS | TAKEDA GMBH (DE) | 2013-06-19 | — | — | EP | claimed |
| US-8455653-B2 | Hydroxy-6-heteroarylphenanthridines and their use as PDE4 inhibitors | TAKEDA GMBH (DE) | 2013-06-04 | — | — | US | claimed |
| US-20130045974-A1 | NOVEL HYDROXY-6-HETEROARYLPHENANTHRIDINES AND THEIR USE AS PDE4 INHIBITORS | NYCOMED GMBH (DE) | 2013-02-21 | — | — | US | claimed |
| US-20120129817-A1 | COMBINATION TREATMENT FOR DIABETES MELLITUS | NYCOMED GMBH (DE) | 2012-05-24 | — | — | US | claimed |
| US-20110257169-A1 | NOVEL HYDROXY-6-HETEROARYLPHENANTHRIDINES AND THEIR USE AS PDE4 INHIBITORS | NYCOMED GMBH (DE) | 2011-10-20 | — | — | US | claimed |
| US-8003798-B2 | Hydroxy-6-heteroarylphenanthridines and their use as PDE4 inhibitors | NYCOMED GMBH (DE) | 2011-08-23 | — | — | US | claimed |
| US-20100179131-A1 | Combination treatment for diabetes mellitus | NYCOMED GMBH (DE) | 2010-07-15 | — | — | US | claimed |
| EP-2189454-A1 | Novel salts of 6-heterocyclyl substituted hexahydrophenanthridine derivatives | Nycomed GmbH (DE) | 2010-05-26 | — | — | EP | claimed |
| US-7718668-B2 | phosphodiesterase inhibitor; drug for respiratory system disorders | NYCOMED GMBH (DE) | 2010-05-18 | — | — | US | claimed |
| EP-1856093-B1 | (2R,4aR,10bR)-6-(2,6-dimethoxypyridin-3-yl)-9-ethoxy-8-methoxy-1,2,3,4,4a,10b-hexahydrophenanthridin-2-ol, HCl salt | NYCOMED GMBH (DE) | 2009-12-02 | — | — | EP | claimed |
| WO-2009109525-A1 | USE OF A SPECIFIC PDE4 INHIBITOR FOR THE TREATMENT AND/OR PROPHYLAXIS OF NON-ALCOHOLIC FATTY LIVER DISEASE | NYCOMED GMBH (DE) | 2009-09-11 | — | — | WO | claimed |
| US-20080194587-A1 | phosphodiesterase inhibitor; drug for respiratory system disorders | NYCOMED GMBH (DE) | 2008-08-14 | — | — | US | claimed |
| US-20080167301-A1 | Respiratory system disorders | ALTANA PHARMA AG (DE) | 2008-07-10 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120129817-A1 | COMBINATION TREATMENT FOR DIABETES MELLITUS | GPR119, IAPP, MTNR1B | PDE4D 1351/4885PDE4A 1218/4885PDE4B 1117/4885 |
| US-20140073636-A1 | NOVEL HYDROXY-6-HETEROARYLPHENANTHRIDINES AND THEIR USE AS PDE4 INHIBITORS | PDE4A, PDE4B, PDE12 | PDE4D 5/4885PDE4A 1/4885PDE4B 2/4885 |
| US-20130045974-A1 | NOVEL HYDROXY-6-HETEROARYLPHENANTHRIDINES AND THEIR USE AS PDE4 INHIBITORS | PDE4A, PDE4B, PDE4C | PDE4D 4/4885PDE4A 1/4885PDE4B 2/4885 |
| US-20110257169-A1 | NOVEL HYDROXY-6-HETEROARYLPHENANTHRIDINES AND THEIR USE AS PDE4 INHIBITORS | PDE4A, PDE4B, PDE4C | PDE4D 4/4885PDE4A 1/4885PDE4B 2/4885 |
| US-20160279120-A1 | NOVEL HYDROXY-6-HETEROARYLPHENANTHRIDINES AND THEIR USE AS PDE4 INHIBITORS | PDE4A, PDE12, PDE4B | PDE4D 5/4885PDE4A 1/4885PDE4B 3/4885 |
| US-20080167301-A1 | Respiratory system disorders | PDE4A, PDE4B, PDE12 | PDE4D 8/4885PDE4A 1/4885PDE4B 2/4885 |
| US-20100179131-A1 | Combination treatment for diabetes mellitus | GPR119, GLP1R, MTNR1B | PDE4D 1248/4885PDE4A 820/4885PDE4B 698/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.